Gilead signs Vir Biotechnology oncology collaboration worth up to $1.9 billion for masked T-cell engagers
Gilead has entered a global oncology collaboration with Vir Biotechnology worth potentially $1.9 billion to develop masked T-cell engagers for solid tumours.
The agreement gives Gilead exclusive licensing rights to three investigational T-cell engager candidates developed using Vir's PRO-XTEN dual-masking technology and AI-enabled protein engineering capabilities.
Vir is eligible for $90 million in upfront consideration, including cash and equity, plus up to $45 million in near-term preclinical milestones and $1.74 billion in additional milestones, alongside royalties on future sales.
Field | Content |
Article Type | Deals |
Companies | Gilead Sciences; Vir Biotechnology |
Deal Type | Global oncology licensing and collaboration agreement |
Potential Deal Value | Approximately $1.9 billion including contingent payments |
Upfront Consideration | $90 million comprising $65 million cash and $25 million equity investment |
Near-Term Milestones | Up to $45 million in preclinical milestones |
Additional Milestones | Up to $1.74 billion |
Royalties | Royalties on future sales; rates not specified in supplied summary |
Licensed Assets | Three investigational solid-tumour T-cell engager candidates |
Technology | PRO-XTEN dual-masking technology and AI-enabled protein engineering |
Therapeutic Modality | Masked T-cell engagers |
Therapeutic Area | Oncology; solid tumours |
Development Stage | Preclinical |
Licensing Rights | Exclusive rights to three collaboration candidates |
Geography | Global |
What Happened | Gilead agreed to license three solid-tumour T-cell engager candidates from Vir Biotechnology in a global oncology collaboration. |
Why It Matters | The agreement expands Gilead's access to next-generation immuno-oncology technology designed to improve the targeting of T-cell engager therapies. |
Strategic Rationale | Gilead gains access to Vir's dual-masking platform while Vir receives financial support and potential downstream payments for its oncology assets. |
Key Takeaway | The collaboration carries approximately $1.9 billion in potential consideration but most payments depend on future milestones. |
What to Watch | Preclinical candidate progression, development milestones, clinical trial initiation and future programme disclosures. |
Primary Source | Vir Biotechnology SEC filing |
Relevant Date | 14 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments